All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Challenges of measuring overall survival in elderly patients with MDS

During the MDS Hub Steering Committee meeting held on November 14, 2022, Theo de Witte chaired a discussion on the challenges of measuring overall survival in elderly patients with myelodysplastic syndromes (MDS), with contributions from Rena Buckstein, Moshe Mittelman, Mikkael Sekeres, and Alex Smith.

Challenges of measuring overall survival in elderly patients with MDS

de Witte outlines the differences in overall and relative survival according to iron toxicity, transfusion dose density, and Revised International Prognostic Scoring System risk group. Moving forward, De Witte goes on to describe the causes of death in patients with lower-risk MDS, including the substantial proportion of patients that die from competing causes, and the committee debates the difficulties in determining whether cause of death is related to MDS. They also discuss the use of relative survival as a parameter when identifying competing reasons for the cause of death in elderly patients with MDS, and how this outcome could be used alongside other clinical data to better elucidate the impact of MDS on mortality.

Your opinion matters

Which is a global phase III trial for MDS that utilizes a biomarker for patient selection? ENHANCE (magrolimab), SELECT-MDS-1 (tamibarotene), VERONA (venetoclax), or STIMILUS-MDS3 (sabatolimab)?
0 votes - 10 days left ...


Subscribe to get the best content related to MDS delivered to your inbox